Background and aims Effective strategies are needed to address dramatic increases in hepatitis C virus (HCV) infection
INTRODUCTION
Globally, chronic hepatitis C virus (HCV) is a leading cause of liver disease and death [1, 2] . In the United States, HCV has a high burden, with 3.4-6 million people currently infected [3] and annual deaths where HCV is an underlying cause now exceeding those from HIV [4] . Injection drug use is the primary mode of HCV transmission [5] . While incidence rates of HCV infection fell between 1989 and 2003, rates have increased more than threefold since 2007 [6] . Many of these infections have been among young people who inject drugs (PWID) in rural areas [7] . Reducing HCV transmission among this subgroup is critical for reducing associated morbidity [8] and achieving elimination [9] .
Accumulating international evidence suggests that syringe service programmes (SSPs) and medicationassisted treatment (MAT, normally involving methadone or buprenorphine replacement therapy in the US) can reduce HCV transmission by 50-80% [10] [11] [12] [13] [14] . Additionally, the availability of all-oral, highly effective direct-acting antiviral (DAA) HCV treatment has heralded a new era where HCV infection can be cured easily in 8-12 weeks [15, 16] . The robust evidence associated with these interventions suggests that treating current HCV infections while simultaneously preventing future infection could reduce HCV transmission significantly in the United States. This is supported by mathematical modelling from non-US settings [17] [18] [19] , and advocated by the World Health Organization (WHO) in their recent global strategy to eliminate viral hepatitis [20] .
In many US regions, the number of PWID has increased markedly due to a growing prescription opioid and heroin epidemic [7] , contributing to a marked increase in parenterally acquired HCV infections [6] . Recently, in Scott County, Indiana, a rural county of 24 000 individuals, a HIV outbreak occurred (192 cases) among people injecting oxymorphone (Opana ® ER), a prescription opioid [21] .
Contact tracing and targeted HIVand HCV testing revealed a sizeable network of PWID with considerable HCV infection (> 70% HCV antibody positivity) and high rates of syringe sharing (68% report ever sharing needles/syringes) and re-use (mean: 12 times before disposal) [22, 23] . Similar to other rural US communities, programmes for preventing HCV/HIV transmission and treating opioid addiction were extremely limited in this setting. In response to the HIV outbreak, the Scott County Health Department implemented an SSP in 2015 and MAT is reported to follow [22] , with ongoing discussions concerning whether or not to scale-up HCV treatment. Due to the increasing HCV epidemic, and limited coverage of prevention and treatment interventions, Scott County provides an important setting for modelling the required scale-up of HCV treatment, MAT and SSP for reducing HCV transmission to low levels. While numerous models [24] [25] [26] [27] have demonstrated that treating HCV-infected PWID, possibly in combination with scaling-up SSPs and MAT [17] , could reduce HCV infection transmission, none have considered the increased requirements in settings with increasing transmission risk, as occurring currently throughout many rural US settings and other settings world-wide [28] [29] [30] [31] .
This study aims to model the HCV impact of scaling-up access to MAT, SSPs and HCV treatment in Scott County to typify other rural US settings with limited existing interventions and increasing HCV epidemics. Specifically, our aims are:
1 With or without scale-up of MAT and SSP services, project the required HCV treatment capacity needed to reduce HCV infection prevalence and incidence among PWID by 90% (as advocated by WHO's elimination strategy [20] ) by 2020/25/30.
2 Project what subsequent treatment rate is needed to maintain impact to 2040. 3 Estimate the degree to which the HCV treatment targets are heightened due to the increasing HCV epidemic occurring in this setting, 4 Determine whether the impact targets are still achievable without allowing treatment of re-infected PWID.
METHODS

Mathematical model description
We developed a dynamic, deterministic, compartmental ordinary differential equation model of HCV transmission among PWID. The modelled PWID population was stratified by HCV (see Supporting information, Fig. S1a ) and intervention status (none, MAT or SSP only, and both; Supporting information, Fig. S1b ). PWID enter the modelled population through a time-varying rate that individuals initiate injecting, and leave through mortality (drug-related or other causes) or permanent cessation from injecting drug use. We did not include HIV because HIV mortality was not expected to be important during the time-span of our projections due to HIV treatment being scaled-up. All new PWID are assumed susceptible to HCV, with no access to SSP or MAT. The model is dynamic, in that it simulates HCV transmission at a per-capita transmission rate dependent upon the current prevalence of chronic HCV infection. The baseline transmission rate for PWID not on MAT or SSP is decreased by fixed multiplicative cofactors (or rate ratios) for PWID on MAT, SSP or both. PWID mix randomly to form potential transmission contacts with other PWID (see Supporting information for details).
Once infected, PWID either develop chronic infection (presence of viraemia) or clear their infection spontaneously and become susceptible to re-infection [32] . Chronically infected PWID remain infected unless treated, whereupon they either achieve a sustained viral response (SVR; virological cure) [16] or fail treatment and remain chronically infected. Treated PWID who achieve SVR become susceptible to re-infection. Conservatively, we assume that re-infection will occur at the same rate as primary infection. We assume PWID who fail treatment or become re-infected can be retreated, but vary this assumption in the sensitivity analysis.
Further model details are shown in the Supporting information.
Model parameterization
Key model input parameters were estimated based on experiences in Scott County, Indiana, with most parameters estimated from state surveillance and contact-tracing data collected during the 2014-15 HIV outbreak. Data from intensive contact-tracing for the HIV outbreak investigation in Indiana [23] Based on state-level acute HCV case reports [34, 35] and data on new opioid-dependent admissions to the drug treatment episode data set (TEDs) for Indiana [36] , we assumed a steady PWID population and HCV epidemic up to 2008 which increased thereafter. Through an increased rate of individuals initiating injecting, we assumed a twoto threefold increase in PWID population size throughout 2008-13 based on increases in opioid-dependent admissions (TEDs) during that period. Through increased HCV transmission risk, we also assumed a four-to sevenfold increase in the annual number of incident HCV infections throughout 2010-14, as observed in the number of acute HCV case reports from Indiana, which increased from approximately 17 annually for 2004-10 to 123 annually for 2011-14. Although known to underestimate the real number of acute infections, the increasing trends in acute cases should still represent a real increase in the rate of new HCV infections, as they are not thought to be due to changes in reporting or case definitions [7] . Importantly, the demographics of these recent acute HCV cases (2015) align closely with the HIV outbreak cases from Scott County (98-99% white, median age 32-34 years and 50-58% male), suggesting that the increase in acute HCV cases occurred among the same pool of PWID as the HIV outbreak.
There is uncertainty in the overall duration that PWID inject drugs, and so we sampled from a wide range of 5-20 years reflecting the young age and short duration of current injecting in rural US sites ( [23, 37, 38] and unpublished Scott County SSP data) and the long injection careers observed among PWID in US cities [39] . We assumed a drug-related mortality rate based on US synthesized data [40] and a non-drug-related mortality rate for the United States [41] .
Prior to 2015, there was no SSP or HCV treatment for PWID in this setting and negligible MAT. SSP opened in March 2015 and reached 200 PWID (33-46% of PWID) by the end of 2015, with the model assuming further scale-up to 50% of PWID by mid-2016. Estimates for the effectiveness of SSP and MAT in reducing an individual's risk of HCV infection were taken from a recent Cochrane systematic review [13] . The duration on MAT or using the SSP were based on US data [42] , after which PWID cease MAT or SSP but can return at existing recruitment rates. Because most PWID are likely to be young and recently infected, we assumed conservative SVR rates for DAA HCV treatment of 90% (varying between 85 and 95%) with 12-week duration [43] .
The model parameters with uncertainty bounds are given in Table 1 .
Model calibration and analyses
While incorporating parameter uncertainty (1000 random samples of parameter distributions in Table 1 ), the model was calibrated (using a least-squared solver in MATLAB) to a sampled estimate for the PWID population size in 2015, increase in PWID population throughout 2008-13, chronic prevalence in 2015 and four-to sevenfold increase in annual incident infections throughout 2010-14. The Supporting information includes more details of the methods.
The model was then run from 2015 to consider the impact of scaling-up SSP from March 2015 and MAT and HCV treatment from mid-2016. We projected the impact of a few illustrative treatment scenarios, and then estimated the annual treatment rate needed to result in a 90% reduction in HCV infection prevalence or incidence from 2016 to 2020, 2025 or 2030. These projections considered the impact both with and without scaling-up both MAT and SSP to 50% coverage alongside increased HCV treatment, with the added assumption that no more than 80% of chronic infections can be treated annually. We then projected the required treatment rates needed to maintain the impact achieved by 2020/25/30 to 2040, and assessed whether the same impact targets for 2020/25/30 could be reached with no retreatment.
Lastly, we undertook a sensitivity analysis to determine the degree to which the increasing epidemic in Indiana may be heightening our required treatment rates for achieving a 90% reduction in incidence and prevalence. The model was recalibrated to the same HCV prevalence in 2015, but assuming no increase in transmission risk or injecting in recent years (see Supporting information), and the treatment rates needed to achieve a 90% reduction in prevalence or incidence were re-estimated.
Uncertainty analysis
To determine which parameter uncertainties are important for driving the variability in our model projections, a linear regression analysis of covariance [44] was performed on the projected number of HCV treatments needed to reduce HCV prevalence or incidence by 90% by 2030 when MAT and SSP are also scaled-up. The proportion of the model outcome's sum-of-squares contributed by each parameter was calculated to estimate the importance of individual parameters to the overall uncertainty. Figure 1 shows that between 2008 and 2010, the model projects that both HCV infection prevalence and incidence decreased due to the increased recruitment of new susceptible PWID initiating injecting. However, this trend reversed when HCV transmission risk increased in 2010. Chronic prevalence increased to 56.0% by 2015, agreeing with available data from the HIV outbreak investigation, but is then projected to reach 83.2% by 2030, and HCV incidence is projected to increase from 44.9 to 66.8 per 100 person-years from 2015 to 2030. Figure 1 also shows the impact of three intervention scenarios, illustrating that scaling-up both SSP and MAT to 50% coverage will be enough to decrease incidence by 2030, but that chronic prevalence will only decrease if this is combined with treating 50 PWID per 1000 annually (7.7% of infections treated in first year).
RESULTS
Baseline epidemic projections and illustrative intervention scenarios
Treatment scale-up needed for reducing and maintaining HCV at low levels Projections in Fig. 2 suggest that a 90% decrease in both HCV infection prevalence and incidence can be achieved by 2030. With no scale-up of SSP and MAT, 159 per 1000 PWID (24.9% of HCV infections treated in the first MAT = medication-assisted treatment; SSP = syringe service program; HCV = hepatitis C virus; SVR = sustained viral response; PWID = people who inject drugs; TEDS = drug treatment episode data set.
year) need to receive HCV treatment annually to reach both these targets. Conversely, if SSP and MAT are both scaled-up to 50% coverage, then the yearly number needing treatment approximately halves to 89 per 1000 PWID (14.5% in the first year).
Projections also suggest that it should be possible to achieve these same impact targets by 2025. When SSP and MAT are scaled-up, a 90% reduction in prevalence and incidence is possible if 121 per 1000 PWID (19.9% of HCV infections treated in first year) are treated annually.
However, if SSP and MAT are not scaled-up then the yearly number needing HCV treatment doubles to 213 per 1000 PWID (34.1% in the first year), although 17% of model simulations suggest it is not possible in this time-frame. Lastly, it is not possible to achieve a 90% reduction in HCV prevalence by 2020, but a 90% decrease in incidence may be achievable (in 55% of simulations) if SSP and MAT are scaled-up and 294 per 1000 PWID (54.9% in the first year) are treated during the first year, with this decreasing in subsequent years.
After achieving a 90% decrease in prevalence and/or incidence by 2030, the Supporting information Fig. S2 shows that prevalence and incidence would rebound quickly (increasing up to 10-fold by 2040) if treatment was not maintained, although the rebound would be smaller (approximately half) if MAT and SSP are scaledup. To maintain the impact achieved on incidence from 2030 to 2040, 21 per 1000 PWID need to be treated annually if MAT and SSP are scaled-up, and 33 per 1000 PWID otherwise (Supporting information, Table S1 ). Fewer treatments are needed to maintain the impact on prevalence.
Uncertainty and sensitivity analysis
There is considerable variability in the projected number of treatments needed to reach different impact targets (Fig. 2) . Analyses of covariance indicate that uncertainty in the chronic HCV infection prevalence in 2015 accounts for most variability in the required number of treatments (with SSP and MAT scaled-up) for achieving a 90% reduction in prevalence or incidence by 2030 (40-42% of variability; Fig. 3 ). Other important parameters were the efficacy estimate for SSP (13% of variability), the PWID population size in 2015 (9-11% of variability) and the drug-related mortality rate (10-12%). The efficacy of SSP and MAT combined and the projected increase in incidence after 2010 also contributed 6-10% of variability each. Other parameters had a small effect.
The baseline model assumed an increasing HCV epidemic and allowed re-treatment of re-infected PWID. If we assume a stable HCV epidemic in Indiana, then twothirds fewer treatments are needed to achieve a 90% decrease in prevalence/incidence (Supporting information, Fig. S3 ). Additionally, without re-treatment it is not possible to decrease prevalence/incidence by 90% by 2030 (Supporting information, Fig. S4 ), with considerable retreatment being needed (24-37% of all treatments) to achieve these targets.
DISCUSSION
Since 2010, dramatic increases in HCV infections in the United States have occurred concurrently with the Figure 1 Hepatitis C virus (HCV) chronic prevalence (a) and incidence (b) among people who inject drugs (PWID) over time for different intervention scenarios. Median projections from 1000 model fits, with 95% credibility intervals shown only for the no-intervention scale-up scenario. SSP denotes syringe service programmes and MAT denotes medication-assisted treatment. Full HR denotes full harm reduction, which is defined as 50% coverage of both SSP and MAT. Hepatitis C virus (HCV) treatment started in mid-2016 with two scenarios being shown (20 or 50 per 1000 PWID being treated annually). Incidence is estimated among susceptible PWID. Fig. 1a also shows the chronic HCV prevalence estimate that the model was calibrated to country's growing opioid epidemic, linked to increasing injection drug use in rural settings [7] . This increase in HCV transmissions was facilitated by limited HCV prevention services in rural settings, which contrasts with most US urban areas which have established harm reduction programmes, and have experienced long-term decreases in HIV transmission [45, 46] . The success of these urban efforts demonstrates the need to expand MAT and SSP in rural settings. However, because no modelling has so far considered similar settings experiencing increasing epidemics, the required scale-up remains unknown.
This modelling study helps to fill this knowledge gap. It demonstrates that achievable scale-up of HCV treatment, when paired with expanded SSP and MAT, could reduce the burden of HCV dramatically among PWID in rural US settings experiencing increasing HCV epidemics. Our findings indicate that a 90% reduction in HCV incidence and prevalence are achievable by 2025 if 20% of currently HCV-infected PWID receive HCV treatment each year with no restriction on re-treatment, and half the population are on MAT or SSP. Due to the small number of PWID in Scott County (estimated at 436-600), these targets should be achievable (< 65 HCV-infected needing treatment annually), suggesting that such rural jurisdictions could be viable settings for conducting demonstration studies to test whether combining HCV treatment with MAT and SSP scale-up can control and eliminate HCV.
To reduce the HCV burden among PWID, this study highlights the importance of scaling-up both HCV treatment and MAT and SSP capacity, with each playing a complementary role. HCV treatment is essential for rapidly , and percentage of infections this translates to in the first year (a) to result in a 90% reduction in chronic HCV prevalence or incidence by 2020, 2025 or 2030, with or without full harm reduction (50% coverage of both SSP and MAT). In both figures, bars show the median projections from a sample of 1000 model runs and whiskers show the 95% credibility intervals. *Fewer than 5% of parameter sets achieved the target. #Only a proportion of parameter sets achieved the target reducing the infection burden to low-levels, which otherwise would take decades with just expanded MAT and SSP. Conversely, scaling-up MAT and SSP dramatically reduces (by half) the required levels of HCV treatment and underlying risk for new infections, which is key for maintaining a low infection burden.
Our projections also highlight the necessity of allowing treatment of re-infections, without which large reductions in HCV transmission are not possible, and the importance of maintaining levels of HCV treatment after the epidemic has reached low levels, because otherwise prevalence and incidence rebound quickly to pre-intervention levels. Crucially, we also illustrate for the first time that much higher treatment rates (threefold higher in our projections) will be needed to reach the WHO elimination targets in settings experiencing increasing HCV epidemics, such as Indiana, other rural US settings and numerous global settings experiencing increased injecting risk [28] [29] [30] [31] . Further analyses need to confirm the generalizability of our findings to other similar settings, with these analyses emphasizing the importance of characterizing a setting's ongoing epidemic accurately when assessing required prevention and treatment needs for tackling HCV.
Limitations
Our analyses are subject to several potential limitations. First, there was limited epidemiological and behavioural data available to parameterize and calibrate the model. To address this, we used data from other US settings [7, 37] when necessary and incorporated parameter uncertainty into our projections.
Secondly, we used acute HCV surveillance data [34, 35] and substance abuse treatment admission data [36] to parameterize the probable increase in HCV infection and injecting drug use occurring in Indiana. Given that these data sources do not capture all new HCV infections and many PWID do not access drug treatment, it is possible that the real-life increases in the HCV epidemic and levels of injection drug use may differ from what these data sets suggest. To counter this, uncertainty was incorporated into these modelled trends and our projections were robust despite this.
Thirdly, we did not incorporate network effects in to our model, which the data suggest contributed to the HIV outbreak in Indiana [23] . This could be an important area of future modelling, as previous modelling has suggested that the network structure of PWID can affect the impact of HCV treatment interventions [47] . Further, due to a lack of data, the model did not incorporate periods of temporary cessation of injecting, but instead assumed that their effect was incorporated into the overall transmission risk of PWID, especially among those on MAT who are more likely to cease injecting temporarily [48] . This model simplification should not have affected our model projections, as illustrated by previous modelling [17, 18] .
Lastly, we did not consider the mechanism by which the scale-up in treatment will be financed. Until recently, the high costs of all oral DAA drugs ($84 000-96 000 per treatment course in 2014) and restrictions within Medicaid programmes [43] (drug/alcohol abstinence and disease severity requirements and restrictions on treatment providers) presented serious obstacles to using HCV treatment as a prevention strategy in the United States [49] . However, the costs of HCV medications are now decreasing [50, 51] (through competition and negotiations), and Medicaid programmes are easing restrictions on HCV treatment [52] , including among those with current drug/alcohol use [Centers for Disease Control and Prevention (CDC), unpublished data]. Economic modelling is now needed to help identify the required HCV drug prices to ensure that HCV treatment-based prevention strategies are cost-effective. Economic modelling should also compare the costs of these HCV treatment-based prevention strategies to the costs of scaling-up MAT and SSP, whose yearly costs are much cheaper per PWID reached (estimated as~$5000 for MAT [53] and~$100 for SSP [54] if 200 syringes are exchanged per year). However, this is not a simple comparison, because HCV treatment exerts a one-off cost per infected PWID, while SSP and MAT exert yearly costs among both infected and susceptible PWID and have other economic benefits.
Comparison with other studies
This is the first modelling study, to our knowledge, to project the impact on HCV transmission of scaling-up combination prevention interventions (MAT and SSP) and HCV treatment for PWID in the U.S. Other analyses in non-US settings have considered the HCV prevention impact of these combined interventions [17, 18] , but have not considered an increasing epidemic setting. Two other analyses have modelled the impact of scaling-up HCV treatment among prisoners [27] or PWID in urban United States [26] . Our modelling builds upon these analyses by considering a rural setting with increasing injection drug use and HCV transmission, which characterizes the main expansion of HCV transmission in the United States. Additionally, we incorporate the important benefits of scaling-up SSP and MAT [12, 14, 55, 56] , which generally have very low coverage in rural settings.
CONCLUSION
Scott County's rapid HIV outbreak occurred in a region that has witnessed increasing injection drug use and HCV transmission during recent years [7] . Many other rural US regions are witnessing similar problems [7] . Like Scott County before the HIV outbreak, many of these regions have insufficient infrastructure or resources to respond effectively, raising serious concerns that similar increases in HCV and HIV infections may occur elsewhere [23, 57] . For areas of the United States and internationally experiencing similar epidemics and suffering analogous limitations in intervention coverage, our findings are of particular importance. They emphasize the need to scaleup HCV treatment, in combination with MAT and SSP, for reducing levels of HCV transmission. Importantly, this would also address current inequities in the provision of MAT and SSP, which will have other benefits [40, [58] [59] [60] [61] . Demonstrating the effectiveness and potential costs and savings of our combined scale-up strategies in the field is an important next step.
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Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article. Figure S3 Required yearly hepatitis C virus (HCV) treatment rate needed to decrease HCV prevalence or incidence by 90% by 2030 under an increasing or stable epidemic. Figure S4 Projected decrease in chronic hepatitis C virus (HCV) prevalence and incidence per 100 person-years if 80% of people who inject drugs (PWID) with a primary infection are treated each year [with or without full harm reduction-50% coverage of both syringe service programme (SSP) and medication-assisted treatment (MAT)] but no re-infections are treated. Table S1 Required yearly number of treatments per 1000 people who inject drugs (PWID) to decrease prevalence and incidence by 90% by 2020/25/30, and to maintain impact until 2040, as well as the overall number of treatments needed between mid-2016 and 2040 to achieve and maintain a 90% reduction in prevalence and incidence. *Only a proportion of model fits achieve the target.
